| Preconditioning approach | The source of cells | Secreted factors or expressed genes | Immunomodulatory effects | Reference |
| Hypoxia | BM-MSCs | IL-6 and IL-8 | monocyte migration in vitro and macrophages in vivo | [25] | IFN-γ | UC-MSCs | IDO and PGE-2 | NK activation and protection from NK cytotoxicity | [26] | IFN-γ and TNF-α | MSCs | Factor H | complement activation | [30] | IFN-γ and TNF-α | BM-MSCs | IDO | generation of M2 macrophages | [27] | IL-1β | UC-MSCs | COX-2, IL-6, and IL-8 | number of M1 macrophages | [28] | IL-1β | BM-MSCs | TNF-α, IL-6, IL-8, and IL-23A, CCL5, CCL20, CXCL1, CXCL3, CXCL5, CXCL6, CXCL10, and CXCL11, and VCAM-1, ICAM-1, and ICAM-4 | recruitment of neutrophils, monocytes, lymphocytes, and eosinophils | [29] | LPS | UC-MSCs | IL-10, TGF-β, and IL-1, IL-6, and TNF-α | generation of M2 macrophages | [31] | LPS and IL-1β | BM-MSCs | PGE-2 | generation of M2 macrophages | [34] | TGF-β | Decidual MSCs | PGE-2 | number of CD14+ CD206+ macrophages | [36] | 3D culture | BM-MSCs | COX-2 and PGE-2 | generation of M2 macrophages and TNF-α production by LPS stimulated macrophages | [37–39] | IFN-γ and TNF-α in 3D culture | BM-MSCs | IDO and IL-6 | suppression of TNF-α production by LPS stimulated macrophages | [40] |
|
|